TrianglePUBLICATIONS · 28183697
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Cancer Discov
- Publication date
- 2017 Apr
- First author
- Drilon A
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Drilon A
- type
- Author
- name
- Siena S
- type
- Author
- name
- Ou SI
- type
- Author
- name
- Patel M
- type
- Author
- name
- Ahn MJ
- type
- Author
- name
- Lee J
- type
- Author
- name
- Bauer TM
- type
- Author
- name
- Farago AF
- type
- Author
- name
- Wheler JJ
- type
- Author
- name
- Liu SV
- type
- Author
- name
- Doebele R
- type
- Author
- name
- Giannetta L
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Drilon A
- type
- Author
- name
- Siena S
- type
- Author
- name
- Ou SI
- type
- Author
- name
- Patel M
- type
- Author
- name
- Ahn MJ
- type
- Author
- name
- Lee J
- type
- Author
- name
- Bauer TM
- type
- Author
- name
- Farago AF
- type
- Author
- name
- Wheler JJ
- type
- Author
- name
- Liu SV
- type
- Author
- name
- Doebele R
- type
- Author
- name
- Giannetta L
- type
- Author
- bibliography ids
- nci-bib-2f4ab38961ab91cb840fb95d
- book metadata
- content sha256
- a56fbdb66d3e8ab16d117ff0c238bd173ba029764ee199cab730cce67dce4397
- document type
- citation
- dois
- 10.1158/2159-8290.CD-16-1237
- electronic publication date
- display
- 2017 Feb 9
- precision
- day
- year
- 2017
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:28183697
- immutable id
- pubmed:28183697@a56fbdb66d3e8ab16d117ff0c238bd173ba029764ee199cab730cce67dce4397
- journal
- abbreviation
- Cancer Discov
- issn electronic
- 2159-8290
- issn print
- 2159-8274
- issue
- 4
- name
- Cancer discovery
- nlm unique id
- 101561693
- pages
- 400-409
- volume
- 7
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 28183697
- provenance
- batch id
- 7a1288ac8bb5f9826304
- provider
- NCBI PubMed ESummary
- record sha256
- 1efc95c2d345a45ce430893bb7a64140fb803e5b7afcbe84d51820c2350a93ed
- response sha256
- 0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
- retrieved at
- 2026-09-09T23:47:23.138359+00:00
- publication date
- display
- 2017 Apr
- precision
- month
- year
- 2017
- publication types
- Clinical Trial, Phase II
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Preserved source evidence · Independent clinical review pending · Not medical advice